CHMP recommends Gilead’s sofosbuvir/velpatasvir/voxilaprevir combo for HCV infection

EMA’s CHMP recommended approval of an MAA from Gilead Sciences Inc. (NASDAQ:GILD) for Vosevi sofosbuvir/velpatasvir/voxilaprevir to treat chronic HCV infection. Gilead said the data included in the application support the use of Vosevi in patients with HCV genotypes 1-6 infection with and without compensated cirrhosis, regardless of prior therapy...